Christopher Gottschalk, MD

A panel of expert neurologists shares advice for community neurologists on preventive migraine treatment and exciting therapies to look forward to.

A discussion on when a patient should be referred to a headache specialist for preventive migraine treatment.

Jessica Ailani, MD, details how the phase 3 ADVANCE trial will shape the research of future agents for preventive migraine treatment.

A key opinion leader discusses the use of oral agents for the preventive treatment of migraine.

Dr Christopher Gottschalk shares how the clinical trial data for CGRP monoclonal antibodies affect patient selection for preventive migraine treatment.

A panel of neurologists review clinical trial data on several CGRP monoclonal antibodies for migraine preventive treatment.

Expert neurologists discuss the use of CGRP monoclonal antibodies to prevent migraines.

Stephanie J. Nahas, MD, MSEd, FAHS, FAAN, provides an overview of the use of onabotulinumtoxinA as a preventive migraine treatment.

A thought leader explains how she involves the patient when selecting novel agents to add to a preventive migraine treatment plan.

An introduction to the use of novel agents for preventive migraine therapy.

An expert panel discusses migraine prevention with the use of behavioral therapies such as cognitive behavioral therapy and stress management.

Dr Andrew Charles shares how he eases patient anxieties over lifestyle changes for preventive migraine therapy.

Rebecca Erwin Wells, MD, MPH, details the effectiveness of lifestyle changes for preventative migraine treatment.

A discussion on how to measure the success of preventative migraine treatment.

Key opinion leaders explain the burden of disease that accompanies preventative migraine treatment.

Expert neurologists share their goals and patient considerations for preventive migraine therapy.

Andrew C. Charles, MD, provides a historical perspective on the agents traditionally used for preventive migraine therapy.

The director of headache medicine and chief of general neurology at Yale Medicine discussed the long-term success the new preventive migraine therapies have shown thus far, and how the lack of safety concerns will improve how they’re utilized.

The director of headache medicine and chief of general neurology at Yale Medicine spoke about the significance of having CGRP inhibitors in migraine treatment, and how eptinezumab fits into the treatment landscape.